Theratechnologies (THTX) Competitors $3.42 +0.03 (+0.86%) Closing price 09/25/2025Extended Trading$3.42 0.00 (0.00%) As of 09/25/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. IVA, CMPS, MNPR, ARCT, SVRA, KALV, GOSS, OPT, BCYC, and AQSTShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Inventiva (IVA), COMPASS Pathways (CMPS), Monopar Therapeutics (MNPR), Arcturus Therapeutics (ARCT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), Opthea (OPT), Bicycle Therapeutics (BCYC), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Its Competitors Inventiva COMPASS Pathways Monopar Therapeutics Arcturus Therapeutics Savara KalVista Pharmaceuticals Gossamer Bio Opthea Bicycle Therapeutics Aquestive Therapeutics Inventiva (NASDAQ:IVA) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Which has more volatility and risk, IVA or THTX? Inventiva has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Do analysts prefer IVA or THTX? Inventiva currently has a consensus price target of $16.14, indicating a potential upside of 195.12%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Theratechnologies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Do institutionals and insiders hold more shares of IVA or THTX? 19.1% of Inventiva shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, IVA or THTX? Theratechnologies has higher revenue and earnings than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M52.59-$199.34MN/AN/ATheratechnologies$84.38M1.86-$8.31M-$0.19-17.99 Does the media favor IVA or THTX? In the previous week, Inventiva had 17 more articles in the media than Theratechnologies. MarketBeat recorded 17 mentions for Inventiva and 0 mentions for Theratechnologies. Inventiva's average media sentiment score of 0.15 beat Theratechnologies' score of 0.00 indicating that Inventiva is being referred to more favorably in the media. Company Overall Sentiment Inventiva Neutral Theratechnologies Neutral Is IVA or THTX more profitable? Inventiva has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Theratechnologies -10.85%N/A -9.83% SummaryInventiva beats Theratechnologies on 11 of the 14 factors compared between the two stocks. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.21M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-17.9922.7785.3627.36Price / Sales1.86486.00596.99137.58Price / CashN/A46.7037.4661.86Price / Book-6.2210.5512.286.81Net Income-$8.31M-$52.58M$3.32B$276.80M7 Day PerformanceN/A0.09%0.59%0.42%1 Month Performance3.61%15.61%10.54%7.86%1 Year Performance165.04%15.13%70.62%41.24% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$3.42+0.9%N/A+163.0%$157.21M$84.38M-17.99140High Trading VolumeIVAInventiva3.238 of 5 stars$6.24-4.4%$15.57+149.5%+112.0%$624.67M$9.95M0.00100Analyst RevisionHigh Trading VolumeCMPSCOMPASS Pathways3.2289 of 5 stars$6.29-2.2%$16.29+158.9%+15.0%$616.90MN/A-3.42120News CoverageAnalyst ForecastGap UpMNPRMonopar Therapeutics2.689 of 5 stars$99.50+0.1%$97.33-2.2%+1,655.7%$613.23MN/A-29.8810Analyst ForecastARCTArcturus Therapeutics3.0523 of 5 stars$21.01-6.9%$50.57+140.7%+2.9%$612.61M$152.31M-9.42180Analyst UpgradeSVRASavara3.0376 of 5 stars$3.46-0.9%$7.50+116.8%-1.4%$603.20MN/A-6.9220Analyst UpgradeKALVKalVista Pharmaceuticals3.7449 of 5 stars$10.96-7.5%$26.43+141.1%-0.3%$598.70M$1.43M-2.78100GOSSGossamer Bio3.8329 of 5 stars$2.41-6.2%$8.50+252.7%+149.0%$584.37M$114.70M-3.89180OPTOpthea0.4213 of 5 stars$3.41+7.2%$1.33-60.9%-30.5%$583.10M$30K0.008News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeBCYCBicycle Therapeutics3.9214 of 5 stars$8.23-1.7%$22.22+170.0%-69.0%$580.10M$19.28M-2.34240News CoverageAnalyst ForecastAQSTAquestive Therapeutics2.6092 of 5 stars$5.97+2.9%$10.29+72.3%+50.1%$578.40M$44.13M-8.53160 Related Companies and Tools Related Companies IVA Competitors CMPS Competitors MNPR Competitors ARCT Competitors SVRA Competitors KALV Competitors GOSS Competitors OPT Competitors BCYC Competitors AQST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
